Year 2025 / Volume 117 / Number 11
Letter
Eosinophilic colitis with favorable response to vedolizumab

682-683

DOI: 10.17235/reed.2024.10660/2024

Cristina Galindo García, Claudia Moreno Pimentel, Reyes Serrano Giménez, Claudia Palomar Ávila, Manuel Castro Fernández, María José Fobelo Lozano,

Abstract
Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity. We report a 34-year-old male with eosinophilic colitis, dependent on corticosteroids, who showed clinical improvement with vedolizumab. Despite a mild flare-up, intensifying vedolizumab resulted in prolonged stability and reduced steroid use over seventeen months. Although corticosteroids are the primary treatment, vedolizumab shows promise in some cases, warranting further investigation to confirm its effectiveness.
New comment
Comments
No comments for this article
References
1. Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Dig Dis Sci. 2019; 64(8):2231-2241. DOI: 10.1007/s10620-019-05617-3
2. Awad C, Bailes B, Horn C, Patel A. Refractory Malignant Eosinophilic Colitis Leading to Ischemic Colitis. ACG Case Rep J. 2023; 10(2): e00991. DOI: 10.14309/crj.0000000000000991
3. Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018; 16(2):1992-1994. DOI: 10.1016/j.cgh.2018.03.024
4. Coutinho Martins Mendes Simões G, Borges V, Bernardes C, Ramos J. Vedolizumab Therapy for Refractory Eosinophilic Enteritis: A Case of Success. Inflamm Bowel Dis. 2023; 29(1): e1-e2. DOI: 10.1093/ibd/izac077
5. Taft TH, Mutlu EA. The Potential Role of Vedolizumab in Concomitant Eosinophilic Esophagitis and Crohn’s Disease. Clin Gastroenterol Hepatol. 2022; 16(11): 1840-1841. DOI: 10.1016/j.cgh.2018.06.022
Related articles

Letter

Eosinophilic gastroenteritis: an uncommon cause of ascites

DOI: 10.17235/reed.2024.10995/2024

Citation tools
Galindo García C, Moreno Pimentel C, Serrano Giménez R, Palomar Ávila C, Castro Fernández M, Fobelo Lozano M, et all. Eosinophilic colitis with favorable response to vedolizumab. 10660/2024


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 10 visits.
This article has been downloaded 0 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 17/07/2024

Accepted: 29/07/2024

Online First: 05/09/2024

Published: 11/11/2025

Article Online First time: 50 days

Article editing time: 482 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology